Tumour-Induced Angiogenesis: A Review

Angiogenesis, the formation of new blood vessels, has become a broad subject and is a very active area for current research. This paper describes the main biological events involved in angiogenesis and their importance in cancer progression. In the first section, a fundamental overview of tumour biology is presented. In the second section, the biology of healthy blood vessels is described and, in the third section, the mechanisms of cell migration and proliferation, which are crucial to angiogenesis, are discussed. In the fourth section, a detailed account of tumour-induced angiogenesis is given, whilst the pro- and anti-angiogenic factors involved are reviewed in the fifth section. Finally, the processes of tumour invasion and metastasis are examined in the sixth section.

[1]  A. Albini,et al.  Assessment of angiogenic potential--the use of AIDS-KS cell supernatants as an in vitro model. , 1992, EXS.

[2]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[3]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[4]  Akiyoshi Uemura,et al.  Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. , 2002, The Journal of clinical investigation.

[5]  L. Liotta,et al.  Tumor invasion and the extracellular matrix. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[6]  G. Yancopoulos,et al.  Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. , 2002, Microvascular research.

[7]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[8]  Z. Han,et al.  Angiogenesis: state of the art. , 1999, International journal of hematology.

[9]  M. Klagsbrun,et al.  Vascular endothelial growth factor and its receptors. , 1996, Cytokine & growth factor reviews.

[10]  I. Herman,et al.  Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.

[11]  M. Detmar,et al.  Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Soff.  Angiostatin and Angiostatin-related Proteins , 2004, Cancer and Metastasis Reviews.

[13]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[14]  J. Mulliken,et al.  The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. , 1999, Journal of cell science.

[15]  A. Woolf,et al.  Hypoxia up-regulates angiopoietin-2, a Tie-2 ligand, in mouse mesangial cells. , 2000, Kidney international.

[16]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[17]  K. Alitalo,et al.  Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Thurston.  Complementary actions of VEGF and Angiopoietin‐1 on blood vessel growth and leakage * , 2002, Journal of anatomy.

[19]  K. Suzuma,et al.  Hypoxia and Vascular Endothelial Growth Factor Selectively Up-regulate Angiopoietin-2 in Bovine Microvascular Endothelial Cells* , 1999, The Journal of Biological Chemistry.

[20]  N. Ferrara,et al.  Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.

[21]  I. Goldberg,et al.  Complex roles of tissue inhibitors of metalloproteinases in cancer , 2002, Oncogene.

[22]  Urban Deutsch,et al.  Angiopoietin-1 induces sprouting angiogenesis in vitro , 1998, Current Biology.

[23]  Wenbiao Liu,et al.  Endothelial cell survival and apoptosis in the tumor vasculature , 2000, Apoptosis.

[24]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[25]  M. Stack,et al.  The Mechanism of Action of Angiostatin: Can You Teach an Old Dog New Tricks? , 2002, Thrombosis and Haemostasis.

[26]  A. Pozzi,et al.  Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis , 2002, Oncogene.

[27]  M. Pepper,et al.  Manipulating angiogenesis. From basic science to the bedside. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[28]  P. D’Amore,et al.  Getting Tie(2)d up in angiogenesis. , 2002, The Journal of clinical investigation.

[29]  A. Foss,et al.  Endothelial Cells of Tumor Vessels: Abnormal but not Absent , 2004, Cancer and Metastasis Reviews.

[30]  Pamela F. Jones.  Tied up (or down?) with angiopoietins , 2004, Angiogenesis.

[31]  P. Indovina,et al.  Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. , 2000, Critical reviews in oncology/hematology.

[32]  Thomas N. Sato,et al.  Angiopoietin and Tie signaling pathways in vascular development. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[33]  J. Bowersox,et al.  Chemotaxis of aortic endothelial cells in response to fibronectin. , 1982, Cancer research.

[34]  G. Yancopoulos,et al.  In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis , 1999, Experimental Neurology.

[35]  M. Stack,et al.  The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[37]  P. Black,et al.  Angiogenesis, Metastasis, and Endogenous Inhibition , 2000, Journal of Neuro-Oncology.

[38]  Kenneth M. Yamada,et al.  Fibronectins—adhesive glycoproteins of cell surface and blood , 1978, Nature.

[39]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[40]  T. Acker,et al.  Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization , 2001, Mechanisms of Development.

[41]  K. Hirschi,et al.  Pericytes in the microvasculature. , 1996, Cardiovascular research.

[42]  N. Bouck,et al.  Multiple forms of angiostatin induce apoptosis in endothelial cells. , 1998, Blood.

[43]  S. Mandriota,et al.  Transforming Growth Factor 1 Down-regulates Vascular Endothelial Growth Factor Receptor 2/flk-1 Expression in Vascular Endothelial Cells (*) , 1996, The Journal of Biological Chemistry.

[44]  J. Folkman,et al.  SELF-REGULATION OF GROWTH IN THREE DIMENSIONS , 1973, The Journal of experimental medicine.

[45]  Gerhard Christofori,et al.  Molecular Mechanisms of Tumor Angiogenesis and Tumor Progression , 2000, Journal of Neuro-Oncology.

[46]  N. MacDonald,et al.  Angiostatin and Endostatin: Endogenous Inhibitors of Tumor Growth , 2004, Cancer and Metastasis Reviews.

[47]  J. Isner,et al.  Chemotactic Properties of Angiopoietin-1 and -2, Ligands for the Endothelial-specific Receptor Tyrosine Kinase Tie2* , 1998, The Journal of Biological Chemistry.

[48]  D E Koshland,et al.  Quantitative analysis of bacterial migration in chemotaxis. , 1972, Nature: New biology.

[49]  Richard A. Lang,et al.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A. Bikfalvi.  Significance of angiogenesis in tumour progression and metastasis. , 1995, European journal of cancer.

[51]  J. McCarthy,et al.  Laminin and fibronectin promote the haptotactic migration of B16 mouse melanoma cells in vitro , 1984, The Journal of cell biology.

[52]  K. Alitalo,et al.  Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis , 2000, Oncogene.

[53]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[54]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[55]  R. Sutherland.  Importance of critical metabolites and cellular interactions in the biology of microregions of tumors , 1986, Cancer.

[56]  Nasim Akhtar,et al.  Angiogenesis assays: a critical overview. , 2003, Clinical chemistry.

[57]  J. Folkman,et al.  Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. , 1984, Science.

[58]  J. Isner,et al.  Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.

[59]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[60]  M. Stack,et al.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. , 1999, The Biochemical journal.

[61]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.

[62]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[63]  H. Dvorak,et al.  Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. , 1989, Journal of the National Cancer Institute.

[64]  L. Orci,et al.  Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro , 1990, The Journal of cell biology.

[65]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[66]  D. Walsh,et al.  Angiogenesis and arthritis. , 1999, Rheumatology.

[67]  V. Schirrmacher.  Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. , 1985, Advances in cancer research.

[68]  G. Nicolson,et al.  Identification, localization, and role of fibronectin in cultured bovine endothelial cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[69]  R. Sutherland.  Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[70]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[71]  J. Wilson,et al.  Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[72]  L. Rosen.  Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[73]  R. Auerbach,et al.  Tumor-induced neovascularization in the mouse eye. , 1982, Journal of the National Cancer Institute.

[74]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[75]  N Paweletz,et al.  Tumor-related angiogenesis. , 1989, Critical reviews in oncology/hematology.

[76]  R. Auerbach,et al.  Angiogenesis in the mouse cornea. , 1979, Science.

[77]  Ferguson Gp,et al.  Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. , 1984 .

[78]  C. Little,et al.  Integrins in vascular development. , 2001, Circulation research.

[79]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[80]  S. Carter,et al.  Principles of Cell Motility: The Direction of Cell Movement and Cancer Invasion , 1965, Nature.

[81]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[82]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[83]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[84]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[85]  P. Shaw,et al.  Dynamics of vascular endothelial-cadherin and beta-catenin localization by vascular endothelial growth factor-induced angiogenesis in human umbilical vein cells. , 2002, Experimental cell research.

[86]  S. Denardo,et al.  Antiangiogenic agents and their promising potential in combined therapy. , 2001, Critical reviews in oncology/hematology.

[87]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[88]  J. Folkman,et al.  Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. , 1977, Microvascular research.

[89]  Sybill Patan,et al.  Vasculogenesis and Angiogenesis as Mechanisms of Vascular Network Formation, Growth and Remodeling , 2000, Journal of Neuro-Oncology.

[90]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[91]  A. Pozzi,et al.  Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. , 1992, EXS.

[92]  N. Brown,et al.  Integrins in development: moving on, responding to, and sticking to the extracellular matrix. , 2002, Developmental cell.

[93]  T. K. Hunt,et al.  Studies on inflammation and wound healing: angiogenesis and collagen synthesis stimulated in vivo by resident and activated wound macrophages. , 1984, Surgery.

[94]  E. Sage,et al.  A novel, quantitative model for study of endothelial cell migration and sprout formation within three-dimensional collagen matrices. , 1999, Microvascular research.

[95]  H. Dvorak,et al.  Stable Expression of Angiopoietin-1 and Other Markers by Cultured Pericytes: Phenotypic Similarities to a Subpopulation of Cells in Maturing Vessels During Later Stages of Angiogenesis In Vivo , 2002, Laboratory Investigation.

[96]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[97]  Elena Bonanno,et al.  Fibronectin promotes the elongation of microvessels during angiogenesis in vitro , 1993, Journal of cellular physiology.

[98]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[99]  MS Pepper,et al.  Extracellular Proteolysis and Angiogenesis , 2001, Thrombosis and Haemostasis.

[100]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[101]  J. Folkman,et al.  Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Y. Cao,et al.  Endogenous angiogenesis inhibitors and their therapeutic implications. , 2001, The international journal of biochemistry & cell biology.

[103]  P. Sharp.  The role of growth factors in the development of diabetic retinopathy. , 1995, Metabolism: clinical and experimental.

[104]  S. Killilea,et al.  Angiogenesis in the female reproductive system , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[105]  M. Stack,et al.  Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. , 1996, Cancer research.

[106]  J. Tonn,et al.  Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. , 2002, The Journal of clinical investigation.

[107]  D A Lauffenburger,et al.  Chemotactic factor concentration gradients in chemotaxis assay systems. , 1981, Journal of immunological methods.

[108]  K. Alitalo,et al.  Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? , 1998, The American journal of pathology.